CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
0.5800
-0.0558 (-8.78%)
At close: Apr 1, 2025, 4:00 PM
0.5846
+0.0046 (0.79%)
After-hours: Apr 1, 2025, 4:48 PM EDT

CytomX Therapeutics Stock Forecast

CTMX's stock price has decreased by -73.39% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 4 analysts with 12-month price forecasts for CytomX Therapeutics stock have an average target of 5.77, with a low estimate of 3.50 and a high estimate of 8.00. The average target predicts an increase of 894.83% from the current stock price of 0.58.

Analyst Consensus: Buy
Target Low Average Median High
Price $3.50 $5.77 $8.00 $8.00
Change +503.45% +894.83% +1279.3% +1279.3%
* Price targets were last updated on May 28, 2024.

Analyst Ratings

The average analyst rating for CytomX Therapeutics stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating Oct '24Nov '24Dec '24Jan '25Feb '25Mar '25
Strong Buy 111111
Buy 222222
Hold 333333
Sell 000000
Strong Sell 000000
Total 666666

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
HC Wainwright & Co.
HC Wainwright & Co.
Hold
Reiterates
n/a
Hold Reiterates n/a n/a Mar 7, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Hold
Reiterates
n/a
Hold Reiterates n/a n/a Jan 7, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Hold
Reiterates
n/a
Hold Reiterates n/a n/a Nov 11, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Hold
Reiterates
n/a
Hold Reiterates n/a n/a Sep 13, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Hold
Reiterates
n/a
Hold Reiterates n/a n/a Aug 22, 2024
More Analyst Ratings

Financial Forecast

Revenue This Year
77.80M
from 138.10M
Decreased by -43.67%
Revenue Next Year
34.35M
from 77.80M
Decreased by -55.85%
EPS This Year
0.10
from 0.38
Decreased by -73.79%
EPS Next Year
-0.50
from 0.10
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
68.43M37.31M53.16M101.21M138.10M77.80M34.35M44.27M
Revenue Growth
154.36%-45.47%42.48%90.38%36.45%-43.67%-55.85%28.88%
EPS
-1.40-1.81-1.51-0.010.380.10-0.50-0.65
EPS Growth
------73.79%--
Forward PE
-----5.86--
No. Analysts -----876
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026202720282029
High 138.6M 88.9M 84.2M
Avg 77.8M 34.3M 44.3M
Low 30.4M n/a n/a

Revenue Growth

Revenue Growth 20252026202720282029
High
0.4%
14.3%
145.2%
Avg
-43.7%
-55.8%
28.9%
Low
-78.0%
- -

EPS Forecast

EPS 2025202620272028
High 0.79 0.15 -0.53
Avg 0.10 -0.50 -0.65
Low -0.43 -0.99 -0.83

EPS Growth

EPS Growth 2025202620272028
High
108.7%
48.6%
-
Avg
-73.8%
- -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.